Silica Corpora

Check out this LinkedIn article that dives deep into The AI Revolution in Biotechnology: Transforming Drug Discovery and Beyond. This insightful read explores how AI is reshaping the biotech landscape, from accelerating drug discovery to unlocking new possibilities in healthcare. Within this article, you'll also find the EY German Biotechnology Report 2024, featuring Silica Corpora. Download the report to see how Silica Corpora is making waves in the biotech industry! https://lnkd.in/ewmaDGCS #BioTech #AI #DrugDesign #SilicaCorpora #GoDeNovo #FutureofHealthcare #Innovation

At Silica Corpora, we are De Novo Antibody Specialists, designing the next generation of antibody therapeutics. A single amino sequence and just few weeks is all we need to intelligently generate leading candidates ready for development. This means fewer trials and reduced animal testing in pre-clinical stages. So why wait? Go De Novo! #BioTech #AI #DrugDesign #SilicaCorpora #GoDeNovo #FutureofHealthcare #Teamwork #Innovation #CompanyCulture

Here’s a glimpse of our groundbreaking technology. Dive into the full details and discover how it can work for you on our website: https://lnkd.in/eNyucBPu. The Generator (De Novo Antibody Design): Feed in your target’s amino acid sequence, and our Generator crafts antibody candidates, delivering precise heavy and light chain sequences aligned with the antibody's variable fragment (Fv). The Discriminator (Epitope-specific Screening): Not only does it predict binding affinity to your specified epitope, but it also rigorously evaluates developability, stability, solubility, and more—ensuring top-notch antibody performance. Optimizer (Antibody Optimization): Our Optimizer customizes your antibody candidates to hit your program’s target product profile (TPP) by tweaking amino acid sequences to perfectly match your desired characteristics. Ep-Mapper (Epitope Mapping): Want to know where your antibody will bind? Ep-Mapper pinpoints the exact binding location on your target epitope with precision. #DrugDesign #SilicaCorpora #ArtificialIntelligence #TogetherForBetter #FutureofHealthcare #AI #BioTech

Ready for your next big opportunity? Silica Corpora is #hiring and looking for two amazing people to join us! If you're passionate about what you do and want to be part of something great, we'd love to hear from you. Check out our job openings and see if there's a fit. Let's grow and break barriers together! #Growth #SilicaCorpora #BioTech #AI #DrugDesign #GoDeNovo #FutureofHealthcare

We’re so happy to unveil a refreshed look for our brand! Check out our profile to see the refined logo in action! 🔹 What’s New? Our updated logo embodies the essence of Silica Corpora: modern, dynamic, and forward-thinking. While staying true to our roots, we’ve refined the design to ensure it represents our commitment to excellence and innovation. 🔹 Why the Change? This upgrade is more than just a visual change. It’s a symbol of our growth, our vision for the future, and our dedication to staying at the forefront of the industry. We believe this refreshed look aligns with our mission to continuously deliver value and break new ground in everything we do. We’re excited to continue this journey with you, now with a new look that reflects the vibrant energy of Silica Corpora! Stay tuned for more updates and insights as we continue to innovate and grow together. #BrandUpdate #Growth #SilicaCorpora #NewLogo #DesignUpgrade #BioTech #AI #DrugDesign #GoDeNovo #FutureofHealthcare

AI is truly reshaping the healthcare landscape! In addition to advancing drug design, GenAI has the potential to revolutionize drug safety monitoring through advanced adverse event validation. Dive into this enlightening article to explore how leveraging generative artificial intelligence could be beneficial in this aspect: https://lnkd.in/dfMFk6Md #AIinHealthcare #DrugSafety #DrugDesign #Innovation #SilicaCorpora #BioTech #AI #GoDeNovo #FutureofHealthcare 

Teamwork in action! Nothing beats collaborating with the amazing people at Silica Corpora. Together, we're driving innovation and success every day. Proud to be part of such a passionate and driven team! #BioTech #AI #DrugDesign #SilicaCorpora #GoDeNovo #FutureofHealthcare #Teamwork #Innovation #CompanyCulture

We’re so happy to introduce Prof. Dr. Hans-Dieter Volk, who is Silica Corpora’s scientific advisor! Prof. (e.m.) Dr. Hans-Dieter Volk is a research group leader at the Institute of Medical Immunology and the BIH Center for Regenerative Therapies (BCRT) at Charité - Universitätsmedizin Berlin and the Berlin Institute of Health (BIH). With an MD/PhD background and as a clinical immunologist, he is a leading expert in personalized immunotherapies, cell product characteristics, and biomarker development for monitoring therapy response. He is the co-founder of spin-off companies CheckImmune GmbH, Cellserve GmbH, and TC-Balance GmbH and coordinates several scientific consortia, including EU-funded projects such as RESTORE and PACE. His professional career began in 1980, and in the following years, he has held significant positions such as Head of the Division of Clinical Immunology at Charité and Head of the Institute of Medical Immunology. Additionally, he was the founding director of the BIH Center for Regenerative Therapies and deputy spokesperson of the Berlin-Brandenburg School for Regenerative Therapies (BSRT) as well as the Einstein Center for Regenerative Therapies (ECRT). Prof. Dr. Volk has authored over 800 peer-reviewed publications and has more than 50,000 citations. His H-index is 116 and his i10-index is 552. His awards include the Humboldt Prize, and he holds memberships in renowned scientific societies and editorial boards of international journals. Currently, he is the Chief Scientific Officer (CSO) of CheckImmune GmbH and TC Balance GmbH and serves on various scientific advisory boards, including those of Bayer and Roche. We’re grateful for the contributions and inputs provided by Prof. Dr. Hans-Dieter Volk, helping us improve and advance towards our goals!

AI and Drug Design experts, we are curious to know your opinions! Meta has announced that they “will release a multimodal Llama AI model over the coming months, but NOT in the EU due to the unpredictable nature of the European regulatory environment.” What do you think is the best way to navigate this landscape? Find our opinion in the comments section and feel free to vote and share your opinions as well. Let’s debate!

Silica Corpora has been recognized by EY as one of Germany’s innovative AI-based biotech solutions startups. In addition to Silica Corpora, other amazing companies are also featured, including: Aignostics, Epsilico, ALACRiS Theranostics GmbH, CrystalsFirst, and many more. We’re excited to see everyone continue to grow! We’re pleased to be acknowledged for our innovative approach and commitment to advancing biotechnology through de novo methods and artificial intelligence. The full report from EY is here: https://lnkd.in/extRKYkE #BioTech #AI #DrugDesign #EYConsultancy #SilicaCorpora #GoDeNovo #FutureofHealthcare